Rapta

In 2023, a group of visionary scientists and investors recognized that drug discovery remained an expensive, time-consuming process with high failure rates. Despite advances in AI, the pharmaceutical industry was still struggling to translate computational insights into viable medicines. This realization sparked the creation of Xaira Therapeutics - co-founded and incubated by ARCH Venture Partners and Foresite Labs - to build an integrated biotechnology company that would truly harness the transformative power of artificial intelligence for drug discovery. Built on the groundbreaking protein design work of Nobel Laureate Dr. David Baker and his team at the University of Washington's Institute for Protein Design, Xaira brings together advanced AI research, expansive data generation, and robust therapeutic product development. The company emerged from stealth mode in 2024 with over $1 billion in funding, ready to revolutionize how we treat disease by making predictions about the right biology to target, the best therapeutics to modulate those targets, and the patients who will benefit most. With offices in South San Francisco, Seattle, and London, Xaira is shifting drug discovery from an empirical science to a precise engineering discipline.

Bloomreach is revolutionizing ecommerce through its AI-powered Loomi platform, which unifies real-time customer and product data to create limitless personalized shopping experiences. By understanding individual customer intent and connecting that intelligence across every channel - from email and SMS to web search and mobile apps - the company enables brands to deliver magical, memorable interactions that drive measurable business growth. Their autonomous search technology goes beyond keyword matching to truly comprehend what shoppers want, while their conversational shopping agents scale the expertise of the best sales associates to guide customers to perfect purchases instantly. Since 2009, Bloomreach has grown to power 25% of all ecommerce experiences in the US and UK, serving over 1,400 global brands including American Eagle, Pandora, and Red Bull. With 900+ employees worldwide and multiple patents for their AI/ML innovations, they process 250 million searches daily and help marketers execute 100,000 email campaigns every day. Their mission - to drive magical and measurable experiences for people and businesses - has made them the trusted Commerce Experience Cloud for retailers, brands, and B2B companies seeking to break the limits of what's possible in digital commerce.

AMTSOL delivers technology solutions for pharmaceutical and biotechnology manufacturers, specialising in the digitalization and automation of GMP-regulated manufacturing environments. The company's work spans the full stack of manufacturing systems - from Level 2 automation through to Level 5 cloud integration and data analytics - and covers the complete project lifecycle, from consultancy and implementation to validation and continuous improvement. Its core service areas include Manufacturing Execution Systems (MES), OT networking, automation, cloud integration, data analytics, and both Computerized System Validation (CSV) and Commissioning, Qualification, and Validation (CQV) services. AMTSOL operates as a vendor-independent, single-partner provider, taking full responsibility for consultancy, project support, and ongoing optimisation across each engagement. GMP compliance and data integrity are central to its delivery model. The company works with pharmaceutical and biotechnology organisations across Singapore, Europe, and the United States, with a focus on Pharma 4.0 adoption and digital transformation. Its stated operational priorities include helping regulated manufacturers increase speed to market and improve operating efficiency.

Sea12 Technologies builds AI-powered workflow orchestration platforms for critical industries, including manufacturing, logistics, construction, and facilities management. Its flagship product, Sea12 Orchestrator, integrates data across enterprises to automate entire departmental workflows end-to-end - going well beyond basic chatbot functionality to eliminate manual data entry and deliver operational efficiency at scale. The platform's technology is built around secure, high-performance backend services and cloud-based workflow execution engines, and its reach extends to millions of people daily. The engineering team brings deep expertise in distributed systems, real-time processing, and large language model (LLM) integration, with talent drawn from leading universities. The core technology stack includes Go, TypeScript, React, PostgreSQL, and Redis. Enterprise partners include Yale, Ritz, Eastern Exterior Wall Systems, and Snap-on. Technical domains: AI workflow orchestration, LLM integration, distributed systems, real-time processing, cloud-based execution Stack: Go, TypeScript, React, PostgreSQL, Redis Industries served: Manufacturing, logistics, construction, facilities management Enterprise partners: Yale, Ritz, Eastern Exterior Wall Systems, Snap-on

Protogon Research builds autonomous AI systems and deploys them directly into financial markets through proprietary trading. The company's stated mission is to develop the most intelligent AI systems in the world, using trading as a practical testbed for AI that genuinely understands the world - rather than one that simply replicates human behaviour or produces superficial outputs. Its long-term research aim is to chart a path toward superintelligence. The company was founded by Rafael Cosman, a serial entrepreneur who previously co-founded Archblock and the TrueFi DeFi protocol. Protogon Research is backed by Zelda Ventures, OVO, and StartX, and is a member of the NVIDIA Inception Program. Protogon's technical work spans machine learning, AI research, trading, and operations. The company describes its technology as original, proprietary, and defensible, and positions itself deliberately apart from traditional quantitative trading firms: the priority is building lasting, transformative AI systems rather than optimising for short-term trading profits. The team is described as highly technical, with deep expertise across its core domains.

Chai Discovery builds AI foundation models designed to predict and reprogram biochemical molecular interactions, with the goal of transforming drug discovery into an engineering discipline. The company's founders are researchers who co-invented protein language modeling and developed state-of-the-art protein folding algorithms. Chai Discovery is backed by OpenAI, Thrive Capital, and General Catalyst, and has a partnership with Eli Lilly. The company's core platform - anchored by its Chai-1 and Chai-2 models - predicts and redesigns interactions between biochemical molecules at atomic precision. Key capabilities include drug-like antibody design against challenging targets and the generation of functional GPCR agonists with minimal screening. The platform has reported a success rate of over 85% for computationally designed molecules meeting drug-like properties, a figure that contrasts with the traditional approach of screening millions or billions of protein sequences over years at a cost of billions of dollars. Chai Discovery's technical work spans several domains: Protein language modeling and folding algorithms Computational protein and antibody design GPCR agonist design Biopharma-focused machine learning Computational prediction of biochemical interactions The company focuses on targets traditionally considered undruggable, positioning its platform as a tool capable of addressing therapeutic challenges that conventional methods cannot efficiently reach.